<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Open-label, multicenter, single-arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes of metastatic melanoma</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author role="corresp">
							<persName><forename type="first">Lisa</forename><surname>Zimmer</surname></persName>
							<email>lisa.zimmer@uk-essen.de</email>
							<affiliation key="aff0">
								<orgName type="department">Department of Dermatology</orgName>
								<orgName type="institution" key="instit1">University Hospital</orgName>
								<orgName type="institution" key="instit2">University Duisburg-Essen</orgName>
								<address>
									<settlement>Essen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="department">Department of Dermatology</orgName>
								<orgName type="institution" key="instit1">University Hospital</orgName>
								<orgName type="institution" key="instit2">University Duisburg-Essen</orgName>
								<address>
									<settlement>Essen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Thomas</forename><forename type="middle">K</forename><surname>Eigentler</surname></persName>
							<affiliation key="aff2">
								<orgName type="department" key="dep1">Department of Dermatology</orgName>
								<orgName type="department" key="dep2">Center for Dermatooncol-ogy</orgName>
								<orgName type="institution">University Medical Center Tübingen</orgName>
								<address>
									<settlement>Tübingen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Felix</forename><surname>Kiecker</surname></persName>
							<affiliation key="aff3">
								<orgName type="department">Department of Dermatology and Allergy</orgName>
								<orgName type="institution">Charité-Universitätsmedizin Berlin</orgName>
								<address>
									<addrLine>Skin Cancer Center</addrLine>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Jan</forename><surname>Simon</surname></persName>
							<affiliation key="aff4">
								<orgName type="department">Department of Dermatology, Venereology and Aller-gology</orgName>
								<orgName type="institution">University Hospital Leipzig</orgName>
								<address>
									<settlement>Leipzig</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Jochen</forename><surname>Utikal</surname></persName>
							<affiliation key="aff5">
								<orgName type="department">German Cancer Research Center (DKFZ)</orgName>
								<orgName type="laboratory">Skin Cancer Unit</orgName>
								<address>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff6">
								<orgName type="department">Department of Dermatology, Venereology and Allergology</orgName>
								<orgName type="institution">University Medical Center Man-nheim, Ruprecht-Karl University of Heidelberg</orgName>
								<address>
									<settlement>Mannheim</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Peter</forename><surname>Mohr</surname></persName>
							<affiliation key="aff7">
								<orgName type="department">Depart-ment of Dermatology</orgName>
								<orgName type="institution">Elbekliniken Stade Buxtehude</orgName>
								<address>
									<settlement>Buxtehude</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Carola</forename><surname>Berking</surname></persName>
							<affiliation key="aff8">
								<orgName type="department">Department of Dermatology and Allergy</orgName>
								<orgName type="institution">Ludwig-Maximilian University</orgName>
								<address>
									<settlement>Munich</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Eckhart</forename><surname>Kämpgen</surname></persName>
							<affiliation key="aff9">
								<orgName type="department">Department of Dermatology</orgName>
								<address>
									<addrLine>Dermatologikum Berlin</addrLine>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Edgar</forename><surname>Dippel</surname></persName>
							<affiliation key="aff10">
								<orgName type="department">Department of Dermatology</orgName>
								<orgName type="institution">Skin Cancer Center Rheinpfalz</orgName>
								<address>
									<settlement>Klinikum Ludwigshafen, Ludwigshafen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Rudolf</forename><surname>Stadler</surname></persName>
							<affiliation key="aff11">
								<orgName type="department">Department of Derma-tology</orgName>
								<orgName type="institution">Medical Centre Minden</orgName>
								<address>
									<settlement>Minden</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Axel</forename><surname>Hauschild</surname></persName>
							<affiliation key="aff12">
								<orgName type="institution">University Department of Dermatology</orgName>
								<address>
									<settlement>Kiel</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Michael</forename><surname>Fluck</surname></persName>
							<affiliation key="aff13">
								<orgName type="department">Department of Dermatology Hornheide</orgName>
								<address>
									<settlement>Münster</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Patrick</forename><surname>Terheyden</surname></persName>
							<affiliation key="aff14">
								<orgName type="department">Department of Dermatology</orgName>
								<orgName type="institution">University of Lübeck</orgName>
								<address>
									<settlement>Lübeck</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Rainer</forename><surname>Rompel</surname></persName>
							<affiliation key="aff15">
								<orgName type="department" key="dep1">Department of Dermatology</orgName>
								<orgName type="department" key="dep2">Clinical Centre Kassel</orgName>
								<address>
									<settlement>Kassel</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Carmen</forename><surname>Loquai</surname></persName>
							<affiliation key="aff16">
								<orgName type="department">Department of Dermatology</orgName>
								<orgName type="institution">University Medical Center</orgName>
							</affiliation>
							<affiliation key="aff17">
								<orgName type="institution">Johannes Gutenberg-University</orgName>
								<address>
									<settlement>Mainz</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Zeinab</forename><surname>Assi</surname></persName>
							<affiliation key="aff2">
								<orgName type="department" key="dep1">Department of Dermatology</orgName>
								<orgName type="department" key="dep2">Center for Dermatooncol-ogy</orgName>
								<orgName type="institution">University Medical Center Tübingen</orgName>
								<address>
									<settlement>Tübingen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Claus</forename><surname>Garbe</surname></persName>
							<affiliation key="aff2">
								<orgName type="department" key="dep1">Department of Dermatology</orgName>
								<orgName type="department" key="dep2">Center for Dermatooncol-ogy</orgName>
								<orgName type="institution">University Medical Center Tübingen</orgName>
								<address>
									<settlement>Tübingen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Dirk</forename><surname>Schadendorf</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Dermatology</orgName>
								<orgName type="institution" key="instit1">University Hospital</orgName>
								<orgName type="institution" key="instit2">University Duisburg-Essen</orgName>
								<address>
									<settlement>Essen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="department">Department of Dermatology</orgName>
								<orgName type="institution" key="instit1">University Hospital</orgName>
								<orgName type="institution" key="instit2">University Duisburg-Essen</orgName>
								<address>
									<settlement>Essen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Open-label, multicenter, single-arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes of metastatic melanoma</title>
					</analytic>
					<monogr>
						<imprint>
							<date/>
						</imprint>
					</monogr>
					<idno type="MD5">6B02C8E8D841067158F689DBACA90585</idno>
					<idno type="DOI">10.1186/s12967-015-0716-5</idno>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:26+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>Trial registration: Clinical Trials.gov NCT01355120 Phase II</term>
					<term>Melanoma</term>
					<term>Cutaneous melanoma</term>
					<term>Mucosal melanoma</term>
					<term>Occult melanoma</term>
					<term>Ipilimumab</term>
					<term>Anti-CTLA-4</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Background: Ipilimumab is an approved immunotherapy that has shown an overall survival benefit in patients with cutaneous metastatic melanoma in two phase III trials.</s><s>As results of registrational trials might not answer all questions regarding safety and efficacy of ipilimumab in patients with advanced melanoma seen in daily clinical practice, the Dermatologic Cooperative Oncology Group conducted a phase II study to assess the efficacy and safety of ipilimumab in patients with different subtypes of metastatic melanoma.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Patients and methods:</head><p><s>We undertook a multicenter phase II study in melanoma patients irrespective of location of the primary melanoma.</s><s>Here we present data on patients with pretreated metastatic cutaneous, mucosal and occult melanoma who received up to four cycles of ipilimumab administered at a dose of 3 mg/kg in 3 week intervals.</s><s>Tumor assessments were conducted at baseline, weeks 12, 24, 36 and 48 according to RECIST 1.1 criteria.</s><s>Adverse events (AEs), including immune-related AEs were graded according to National Cancer Institute Common Toxicity Criteria (CTC) v.4.0.</s><s>Primary endpoint was the OS rate at 12 months.</s></p><p><s>Results: 103 pretreated patients received at least one dose of ipilimumab, including 83 cutaneous, seven mucosal and 13 occult melanomas.</s><s>1-year OS rates for cutaneous, mucosal and occult melanoma were 38 %, 14 % and 27 %, respectively.</s><s>Median OS was 6.8 months (95 % CI 5.3-9.9)</s><s>for cutaneous, 9.6 months (95 % CI 1.6-11.1)</s><s>for mucosal, and 9.9 months (lower 95 % CI 2.3, upper 95 % CI non-existent) for occult melanoma.</s><s>Overall response rates for cutaneous, mucosal and occult melanoma were 16 %, 17 % and 11 %, respectively.</s><s>Eleven patients had partial response (16 %) and ten patients experienced stable disease (14 %), none achieved a complete response.</s><s>Treatment-related AEs were observed in 71 patients (69 %), including 20 grade 3-4 events (19 %).</s><s>No new and unexpected safety findings were noted.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Conclusions:</head><p><s>Ipilimumab is a treatment option for pretreated patients with advanced cutaneous melanoma seen in daily routine.</s><s>Toxicity was manageable when treated as per protocol-specific guidelines.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Background</head><p><s>From a clinical like from a scientific perspective, the recent advances in cancer immunotherapy have been acknowledged as a major breakthrough <ref type="bibr" target="#b0">[1]</ref>.</s><s>Especially for melanoma patients, immune checkpoint inhibitors begin to witness an enormous therapeutic potential, resulting very recently in the approval of the first-in-class anti-programmed-death-receptor-1 (PD-1) inhibitors nivolumab and pembrolizumab for the treatment of unresectable or metastatic melanoma <ref type="bibr" target="#b1">[2]</ref><ref type="bibr" target="#b2">[3]</ref><ref type="bibr" target="#b3">[4]</ref><ref type="bibr" target="#b4">[5]</ref>.</s></p><p><s>The cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) inhibitor ipilimumab has been authorized for use in advanced, metastatic melanoma in the United States and in the European Union-as in many other countries worldwide since-on basis of two pivotal phase III studies <ref type="bibr" target="#b5">[6,</ref><ref type="bibr" target="#b6">7]</ref>.</s><s>CTLA-4, a native regulator of T cell activation, downregulates T-cell function through a variety of mechanisms, and finally induces T-cell cycle arrest <ref type="bibr" target="#b7">[8]</ref>.</s><s>Because many of the immune checkpoints are regulated by ligand-receptor interactions, CTLA-4 can be easily blocked by monoclonal antibodies or recombinant ligand-like proteins that block CTLA-4 as a negative regulator of immunity, hence enhancing natural antitumor immunity <ref type="bibr" target="#b8">[9]</ref>.</s></p><p><s>Serving as the first mechanistically defined immune checkpoint inhibitor, ipilimumab has been intensely investigated in clinical registrational trial settings <ref type="bibr" target="#b5">[6,</ref><ref type="bibr" target="#b6">7]</ref> in patients with cutaneous melanoma, the most frequent melanoma subgroup with morphological and molecular distinctions from other clinical disease subgroups <ref type="bibr" target="#b9">[10]</ref>.</s><s>However, results of registrational trials might not answer all questions regarding safety and efficacy of ipilimumab in advanced melanoma patient cohorts seen in daily routine.</s></p><p><s>Here we report the results of the open-label, multicenter, single-arm phase II DeCOG trial to further evaluate the efficacy and safety of 3 mg/kg ipilimumab in pretreated patients with cutaneous, mucosal and occult metastatic melanoma seen in daily routine in interdisciplinary skin cancer units in Germany.</s><s>Data for patients with ocular melanoma are reported elsewhere <ref type="bibr" target="#b10">[11]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Patients and methods</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Patients</head><p><s>Eligibility criteria included documented unresectable stage III or stage IV metastatic cutaneous, occult, mucosal and ocular melanoma according to American Joint Committee on Cancer cutaneous melanoma staging criteria <ref type="bibr" target="#b11">[12]</ref>.</s><s>Patients who had received at least one prior systemic therapy were eligible.</s><s>Previous systemic treatment had to be completed ≥28 days before receiving ipilimumab.</s><s>Additional requirements included age ≥18 years, Eastern Cooperative Oncology Group (ECOG) performance status ≤2, life expectancy of ≥6 months (estimation of life expectancy was at the discretion of the participating investigators), measurable disease according to Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 <ref type="bibr" target="#b12">[13]</ref>, adequate bone marrow, renal and hepatic function.</s><s>Patients with a history of active autoimmune disease and chronic use of systemic corticosteroids were excluded.</s><s>Patients with asymptomatic, radiographically stable previously treated or untreated brain metastases were eligible.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Study design</head><p><s>This multicenter, open-label, phase II study (DeCOG-MM-PAL11-Trial; CA184-137) was conducted in two parts.</s><s>Part 1 of the study was open for recruitment from May 2011 to August 2011; in an Additional file 1: Figure <ref type="figure" target="#fig_0">S1</ref> the patient flow is described.</s><s>This part allowed recruitment of pretreated melanoma patients irrespective of location of the primary melanoma.</s><s>Part 2, which was only eligible for patients with pretreated or treatment-naïve metastatic ocular melanoma to allow for a valid analysis of this subgroup, was closed on September 30, 2012.</s><s>Data from part 1 and 2 for patients with ocular melanoma are reported elsewhere <ref type="bibr" target="#b10">[11]</ref>.</s><s>Twenty-five Dermatologic Cooperative Oncology Group (DeCOG) skin cancer units in Germany participated.</s><s>The study was approved by institutional ethics committee University Duisburg-Essen (approval number 10-4531) and the German competent authority Paul-Ehrlich-Institute (Langen, Germany, approval number 1233), and conducted in accordance with the Declaration of Helsinki/Good Clinical Practice.</s><s>All patients gave written informed consent.</s><s>The protocol for this trial is available as Additional file 2. Ipilimumab was administered intravenously over 90 min at a dose of 3 mg/kg every 3 weeks for a total of four infusions.</s><s>Patients with progressive disease (PD) at ≥3 months from week 12 assessment following stable disease (SD), an initial partial (PR) or complete response (CR) were eligible for re-induction with ipilimumab following at the same dosage.</s><s>Dose reduction was not allowed, but skipping of one dose of ipilimumab was recommended when adverse events (AE) occurred.</s><s>Rapid disease progression, intolerable toxicity or patient withdrawal led to treatment discontinuation.</s><s>The primary endpoint was the overall survival (OS) rate at 12 months.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Assessments</head><p><s>Regular assessments, including a physical examination and standardized blood testing, were carried out at baseline and every 3 weeks during induction and re-induction phases.</s><s>Tumor assessments were conducted at baseline, weeks 12, 24, 36 and 48 using the RECIST version 1.1 <ref type="bibr" target="#b12">[13]</ref>.</s><s>Adverse events (AEs) were graded according to the National Cancer Institute Common Toxicity Criteria (CTC version 4.0).</s><s>All AEs were recorded from the time of the first ipilimumab administration until 70 days after treatment discontinuation.</s><s>AEs were defined as an immune-related AE (irAE) if they were associated with drug exposure, consistent with an immune phenomenon and if other causes were ruled out.</s><s>IrAE management was based on protocol-specific treatment algorithms.</s><s>All AEs that were definitely, probably or possibly related to study drug were defined as related AEs.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Statistical methods</head><p><s>This report includes results based on the data cutoff of December 6, 2013.</s><s>Patient and disease characteristics were analyzed using descriptive statistics.</s><s>Categorical values were expressed as counts and percentage whereas continuous values were expressed as median and range values.</s><s>OS was defined as the time from the first administration of ipilimumab to death from any cause.</s><s>Patients last known to be alive were censored at the date of last contact.</s><s>Progression-free survival (PFS) was defined as the time from the first dose of ipilimumab to the first date of documented progression as per RECIST, or date of death, whichever came first.</s><s>Patients last known to be alive and progression-free were censored at the date of last contact.</s><s>PFS rate at 6 months was defined as the proportion of patients being alive and without progress 6 months after the first ipilimumab administration.</s><s>Patients with unknown survival status or unknown status of progression at 6 months were censored.</s><s>The 1and 2-year survival rates were defined as the proportion of patients being alive 12 or 24 months after their first ipilimumab administration.</s><s>Patients with unknown survival status at 12 or 24 months were censored.</s><s>OS, PFS, PFS rate at 6 months, 1-and 2-year survival rates were estimated by the Kaplan-Meier method.</s><s>For medians of OS and PFS, 95 % confidence intervals (CIs) were calculated using the Brookmeyer and Crowley method.</s><s>The log-rank test was used to compare the 1-year and 2-year OS rates in patients with cutaneous melanoma between several subgroups, i.e. the BRAF mutational status, the presence of brain metastases, the lactate dehydrogenase (LDH) level prior to receiving ipilimumab [&lt;2-fold upper level norm (ULN) vs. ≥2× ULN], the number of ipilimumab doses (&lt;4 vs. 4), and the absolute lymphocyte count (ALC) (&lt;1000/µl vs. ≥1000/µl) before the first (week 1), the second (week 4) and the third dose (week 7) of ipilimumab.</s><s>Due to small sample sizes comparisons of 1-year and 2-year OS rates in patients with mucosal and occult melanoma were not done.</s><s>Two sided p values were evaluated and a p value of &lt;0.05 was considered statistically significant.</s><s>All variables with significant differences between their stratifications regarding the overall survival were included in a multivariate Cox proportional hazards model.</s><s>To determine potential predictors, all independent covariates (LDH, number of ipilimumab doses, ALC week 4, brain metastases), were entered into a backward Cox regression model for the overall survival.</s><s>The stay level was p = 0.05.</s><s>All covariates being still significant were considered as potential predictors.</s><s>For the hazard ratio, 95 % CIs were calculated using the Wald method.</s><s>The overall response rate (ORR) was defined as the proportion of patients with PR and CR whereas the disease control rate (DCR) was defined as the proportion of patients with CR, PR and SD.</s><s>Lost to follow-up was documented if the patient did not respond to phone calls (3 times) and to a written invitation.</s><s>Analyses were carried out using SAS software, version 9.3 (Cary, NC, USA).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Patients</head><p><s>Between May to August 2011, 103 patients were enrolled and received at least one dose of ipilimumab, including 83 patients with cutaneous melanoma, 13 with occult melanoma and seven with mucosal melanoma (Table <ref type="table" target="#tab_0">1</ref>).</s><s>Baseline patient characteristics are reported in Table <ref type="table" target="#tab_0">1</ref>.</s><s>All 103 patients had received previous systemic anti-cancer treatment, including chemotherapy, immunotherapy, and targeted agents (Table <ref type="table" target="#tab_0">1</ref>).</s><s>The most common chemotherapies were dacarbazine and carboplatin/paclitaxel given in 73 (71 %) and 30 (29 %) of all patients.</s><s>None had previously received ipilimumab but 18 patients had undergone previous immunotherapy treatment with interferon α or vaccination.</s><s>31 patients presented with brain metastases at study entry, with similar proportions observed across the different melanoma subtypes (Table <ref type="table" target="#tab_0">1</ref>).</s><s>Sixty-four patients (62 %) completed the induction phase, including 52 patients with cutaneous, four with mucosal and eight with occult melanoma.</s><s>Three patients with cutaneous melanoma experienced PR at week 12 and were reinduced after 91, 232 and 217 days, respectively (Table <ref type="table" target="#tab_3">2</ref>).</s><s>The median number of doses received in the induction phase was four (range 1-4).</s><s>Among the 39 patients (38 %) who did not complete the induction phase, 11 (11 %) died, 16 (16 %) developed PD, eight (8 %) had intolerable AEs and four (4 %) withdrew their informed consent.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Efficacy</head><p><s>The 1-year rate for OS was 38 % (95 % CI 27-49) for cutaneous melanoma, 14 % (95 % CI 1-47) for mucosal melanoma, and 27 % (95 % CI 5-57) for occult melanoma.</s><s>2-year OS rates for cutaneous and occult melanoma were 22 % (95 % CI 13-33) and 27 % (95 % CI 5-57), respectively.</s><s>All of the patients with mucosal melanoma died before month 24 after the first ipilimumab  <ref type="figure" target="#fig_0">1c</ref>) months, respectively.</s><s>Seventy of 103 patients were evaluable for efficacy assessment (Table <ref type="table" target="#tab_4">3</ref>).</s><s>Among the 33 patients (32 %) who were not assessable, 22 died before the assessment of change in tumor burden (including 13 with brain metastases), three developed PD (including two with brain metastases), three had intolerable AEs, one had no measurable disease at baseline, three withdrew their informed consent (including one with brain metastases) and one was lost to follow-up.</s></p><p><s>The DCR was 29 % for cutaneous, 50 % for mucosal and 22 % for occult melanoma (Table <ref type="table" target="#tab_4">3</ref>).</s><s>Overall response rates for cutaneous, mucosal and occult melanoma were 16 %, 17 % and 11 %, respectively (Table <ref type="table" target="#tab_4">3</ref>).</s><s>Among the 70 patients evaluable for response, the overall response rate for 15 patients with brain metastases was 13 %: a response rate similar to the one found for the remaining 55 patients without brain metastases (16 %).</s><s>Of the 15 patients with brain metastases seven patients had intracranial SD, seven intracranial PD and one patient experienced intracranial CR.</s><s>In total, ten patients showed similar response pattern in intracranial and extracranial metastases and five patients had different response pattern, e.g. in one patient an intracranial response (CR) was observed, unfortunately associated with extracranial PD (Additional file 3: Table <ref type="table" target="#tab_4">S3</ref>).</s></p><p><s>The 1-year OS rate was higher in patients with cutaneous melanoma who had no brain metastases (51 % vs. 12 %, p &lt; 0.0001, Fig. <ref type="figure" target="#fig_1">2a</ref>), in patients with a LDH level &lt;2× ULN (42 % vs. 19 %, p = 0.0007), in patients who received four ipilimumab doses (53 % vs. 14 %, p &lt; 0.0001; Fig. <ref type="figure" target="#fig_1">2b</ref>), and in patients with an ALC ≥1000/ µl before the second dose of ipilimumab (week 4) (47 % vs. 22 %, p = 0.002; Fig. <ref type="figure" target="#fig_1">2c</ref>).</s><s>The apparent better OS observed in patients who received all four ipilimumab doses, could be solely based on a time dependent bias, as receiving four doses of ipilimumab required surviving &gt;10 weeks after therapy initiation.</s><s>This only applied to 39 % of the patients who received &lt;4, but not surprisingly all with four doses of ipilimumab.</s><s>BRAF mutational status, the ALC before the first and the third dose of ipilimumab in patients with cutaneous melanoma were not associated with OS.</s><s>In a multivariate analysis, the factors independently associated with better OS were the administration of four ipilimumab doses (e.g.</s><s>patients with less than 4 doses were at higher risk of death; hazard ratio 4.3, 95 % CI 2.3-8.0), an ALC ≥1000/µl before the second dose of ipilimumab (week 4) (e.g.</s><s>patients with ALC &lt;1000/µl were at higher risk of death; hazard ratio 2.0; 95 % CI 1.1-3.8),</s><s>and the absence of brain metastases (e.g.</s><s>patients with brain metastases were at higher risk of death; hazard ratio 1.9, 95 % CI 1.0-3.5).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Safety</head><p><s>Ninety-eight of 103 patients (95 %) experienced one or more AEs ( treatment-related AEs were irAEs, occurring in 52 patients (51 %).</s><s>Most common irAEs were gastrointestinal disorders-diarrhea and colitis, skin-related toxic effects-pruritus and rash, and hepatic disordersincreased alanine aminotransferases (ALT) and aspartate aminotransferases (Table <ref type="table" target="#tab_1">4</ref>).</s><s>The most frequent grade 3 or 4 irAEs were diarrhea and colitis, noted in ten (10 %) and 5 patients (5 %), respectively.</s><s>There was one patient with a gastrointestinal perforation due to grade 3 colitis and diarrhea.</s><s>After surgery and treatment with 2 mg/ kg methylprednisolone intravenous, diarrhea and colitis improved and corticosteroid therapy was tapered slowly over 6 weeks.</s><s>Immune-related AEs were generally reversible when managed as per protocol-specific treatment</s></p><p><s>-</s></p><formula xml:id="formula_1">Hand-foot-syndrome 1 (1) - - - - - 1<label>(1)</label></formula><p><s>-</s></p><formula xml:id="formula_2">irGastrointestinal disorders 39 (47) 15<label>(18) 2 (28) 1 (14) 8 (62) 4 (31) 49 (48) 20 (20) Colitis 6 (7) 4 (5) - - 1 (8) 1 (8) 7 (7) 5 (5) Diarrhea 25 (30) 8 (10) 1 (14) 1 (14) 4 (31) 1 (8) 30 (29) 10 (10)</label></formula><p><s>GI-perforation 1</s></p><formula xml:id="formula_3">Other b 7 (9) 2 (2) 1 (14) - 3<label>(1) 1 (1) - - - - 1 (1) 1 (1)</label></formula><p><s>irEndocrine disorders</s></p><formula xml:id="formula_5">5 (6) 1 (1) - - - - 5<label>(5) 1 (1) Hypophysitis 4 (5) 1 (1)</label></formula><formula xml:id="formula_6">- - - - 4 (4) - Hypothyroidism 1 (1) - - - - - 1<label>(1)</label></formula><p><s>-</s></p><formula xml:id="formula_7">irHepatic disorders 4 (5) 1 (1) - - - - 4<label>(4) 1 (1)</label></formula><formula xml:id="formula_8">Increased ALT 1 (1) - - - - - 1<label>(1)</label></formula><p><s>-</s></p><formula xml:id="formula_9">Increased AST 1 (1) - - - - - 1<label>(1) - Other 2 (2) 1 (1) - - - - 2 (2) 1 (1)</label></formula><p><s>guidelines.</s><s>Most of the irAEs resolved with corticosteroid therapy.</s><s>None of the patients required additional immunosuppression with infliximab or mycophenylate mofetil.</s><s>Treatment related non-irAEs included anemia, fatigue, bone pain, fever, nausea and vomiting.</s><s>There was no treatment-related death.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Discussion</head><p><s>This prospective DeCOG phase II trial evaluated the efficacy and safety of ipilimumab in a cohort of 103 patients with 83 pretreated metastatic cutaneous, seven mucosal and 13 occult melanoma.</s><s>The distribution rate of these clinical subgroups in our trial-considered as representative for a daily routine hospital setting-has been very similar to the rates reported for a named-patient program in Germany with approximately 200 patients <ref type="bibr" target="#b13">[14]</ref> [Data not disclosed].</s><s>In both multi-center studies, patients with pretreated cutaneous melanoma represented approximately 80 % of all patients; patients with mucosal melanoma (DeCOG: 7 %; expanded access program (EAP) Germany: 5 %) and with occult melanoma (DeCOG: 13 %; EAP Germany: 11 %) were enrolled less frequently.</s><s>Very similar distribution rates were also reported from large EAPs with 3 mg/kg ipilimumab in Italy, Spain and Australia <ref type="bibr" target="#b14">[15]</ref><ref type="bibr" target="#b15">[16]</ref><ref type="bibr" target="#b16">[17]</ref> (Additional file 4: Table <ref type="table" target="#tab_5">S4</ref>), with rather constant percentages of mucosal melanoma patients (ranging from 7 to 8 %) and occult melanoma patients (6-8 %) enrolled.</s></p><p><s>The reported OS rate at 12 months of 38 % for patients with cutaneous melanoma is fitting with data from several other studies (range 33-38 %) (Additional file 4: Table <ref type="table" target="#tab_5">S4</ref>) enrolling daily clinical routine patients with a high portion of this melanoma subgroup <ref type="bibr" target="#b13">[14]</ref><ref type="bibr" target="#b14">[15]</ref><ref type="bibr" target="#b15">[16]</ref><ref type="bibr" target="#b16">[17]</ref>; a report on an EAP run in the Netherlands and the UK with cutaneous melanoma patients only also resulted into an 1-year OS rate of 38 % <ref type="bibr" target="#b17">[18]</ref>.</s><s>In a pivotal, randomized phase II dose-ranging study, in which patients with ocular and mucosal melanoma were excluded as well as patients with brain metastases, the OS rate at 12 months for the ipilimumab 3 mg/kg arm of a similar size was 39 % <ref type="bibr" target="#b18">[19]</ref>.</s><s>2-year survival rates in our study <ref type="bibr">(22 %)</ref>, in the Dutch-UK expanded access cohort (23 %) <ref type="bibr" target="#b17">[18]</ref> and in the pivotal phase II study (24 %) <ref type="bibr" target="#b18">[19]</ref> were very similar too: these rates also match with recently published data from a pooled analysis of long-term survival data from approximately 5000 patients included in the ipilimumab pivotal clinical trials and the EAP <ref type="bibr" target="#b19">[20]</ref>.</s><s>This landmark analysis depicts a plateau in the iplilimumab survival curves at around 20 %.</s></p><p><s>Compared to skin melanoma, primary noncutaneous melanomas show a less favorable outcome when treated with 3 mg/kg ipilimumab.</s><s>For occult and mucosal melanoma we found lower 1-year survival rates with 27 and 14 %, respectively.</s><s>Due to the very low patient numbers, the figures for mucosal melanoma are difficult to interpret.</s><s>However, similar findings were reported from the Australian EAP <ref type="bibr" target="#b16">[17]</ref>-the only other study so far reporting OS outcomes for cutaneous versus noncutaneous melanoma treated with 3 mg/kg ipilimumab.</s><s>Here, the median OS for cutaneous melanoma was twice as high (11.7 months) as for patients with uveal (5.7 months) or mucosal (5.8 months) melanoma.</s><s>Again, the low number of patients with noncutaneous melanoma resulted into very huge confidence intervals.</s><s>In the Italian EAP, a median OS of 6.4 months was reported for 71 patients with mucosal melanoma <ref type="bibr" target="#b20">[21]</ref>-a value slightly below the 6.8 months reported for the overall patient collective of around 850 patients, 74 % of them with cutaneous melanoma <ref type="bibr" target="#b14">[15]</ref>.</s><s>However, survival data for cutaneous melanoma patients only were not reported from Italy.</s><s>A retrospective case series from the US similarly found a median OS of 6.4 months for a cohort of 34 mucosal melanoma patients <ref type="bibr" target="#b21">[22]</ref>.</s><s>These estimates all remain below the median OS of 10-11 months, reported for primarily cutaneous melanoma patient collectives in the pivotal phase III trial with highly selected patients and a retrospective long-term-survival landmark analysis <ref type="bibr" target="#b5">[6,</ref><ref type="bibr" target="#b19">20]</ref>.</s><s>The observed OS difference may be explained by the acknowledged aggressive character of mucosal melanoma; this clinical subgroup represents distinct clinicopathological and molecular features linked with reduced survival rates <ref type="bibr" target="#b9">[10,</ref><ref type="bibr" target="#b20">21]</ref>.</s><s>For the 13 patients with occult melanoma, data for comparison of efficacy are not available from other studies (Additional file 4: Table <ref type="table" target="#tab_5">S4</ref>).</s><s>Due to the small sample, the inconclusive outcomes in terms of median overall survival and 1-year survival rate do not allow any conclusion, although a better survival outcome for stage IV patients with nodal metastasis of melanoma from an unknown primary (MUP) versus melanoma from a known primary has been reported in a retrospective cohort study <ref type="bibr" target="#b22">[23]</ref>.</s><s>The relative high portion of occult melanoma patients in our initial study cohort, as compared to literature <ref type="bibr" target="#b23">[24,</ref><ref type="bibr" target="#b24">25]</ref>, is considered as a selection effect, because such patients usually cannot be included into clinical trials.</s></p><p><s>In our study, four doses of ipilimumab, the absence of brain metastases, and an ALC ≥1000/µl at week 4 were identified as factors independently associated with a better OS in the 83 patients with cutaneous melanoma.</s><s>These findings enforce the current level of evidence gained by several studies that the completion of the four-dose-induction phase <ref type="bibr" target="#b13">[14,</ref><ref type="bibr" target="#b25">26]</ref>, the absence of brain metastases <ref type="bibr" target="#b13">[14]</ref><ref type="bibr" target="#b14">[15]</ref><ref type="bibr" target="#b15">[16]</ref>, and high ALC counts and/or changes in ALC pharmacodynamics <ref type="bibr" target="#b15">[16]</ref><ref type="bibr" target="#b16">[17]</ref><ref type="bibr" target="#b17">[18]</ref><ref type="bibr" target="#b25">[26]</ref><ref type="bibr" target="#b26">[27]</ref><ref type="bibr" target="#b27">[28]</ref><ref type="bibr" target="#b28">[29]</ref> are predictive for a significant prolongation of survival of ipilimumabtreated patients.</s><s>Investigations continue to further clarify the role of ALC as an on-treatment pharmacodynamic marker of ipilimumab activity.</s><s>However, biomarkers to select upfront the right patients for ipilimumab use are still missing.</s><s>The identification of an immunological biomarker during the development of the anti PD-1 inhibitor nivolumab <ref type="bibr" target="#b29">[30,</ref><ref type="bibr" target="#b30">31]</ref> and the subsequent validation of PD-L1 expression in the course of the pivotal phase III trials <ref type="bibr" target="#b1">[2,</ref><ref type="bibr" target="#b32">[32]</ref><ref type="bibr" target="#b33">[33]</ref><ref type="bibr" target="#b34">[34]</ref> documents the potential and usefulness of such an approach.</s><s>Ultimately, melanoma patients are expected to further benefit from a combination of such immunological treatment approaches, administered either sequentially <ref type="bibr" target="#b1">[2,</ref><ref type="bibr" target="#b3">4,</ref><ref type="bibr" target="#b4">5]</ref> or concomitantly <ref type="bibr" target="#b35">[35]</ref>.</s><s>Furthermore, two PD-1 inhibitors, pembrolizumab <ref type="bibr" target="#b34">[34]</ref> and nivolumab <ref type="bibr" target="#b33">[33]</ref>, as well as the combination of nivolumab and ipilimumab have been shown to improve the progression-free <ref type="bibr" target="#b33">[33,</ref><ref type="bibr" target="#b34">34]</ref> and overall survival <ref type="bibr" target="#b34">[34]</ref> compared with ipilimumab in phase 3 clinical trials in patients with metastatic melanoma.</s></p><p><s>Similar to previous studies of ipilimumab at a dose of 3 mg/kg <ref type="bibr" target="#b5">[6,</ref><ref type="bibr" target="#b36">36]</ref> immune-related dermatological AEs, i.e. pruritus and rash, and immune-related gastrointestinal AEs, i.e. diarrhea and colitis were the most frequent treatment-related adverse events.</s><s>The rate of grade 3 and 4 treatment-related AEs in patients with cutaneous melanoma were in line with the results of the pivotal phase III trial of ipilimumab <ref type="bibr" target="#b5">[6]</ref>.</s><s>Most of the irAEs were reversible when managed as per protocol-specific treatment guidelines and resolved with systemic glucocorticosteroid therapy.</s><s>No new and unexpected safety findings were noted except one death with unknown cause was reported and the causal relationship to ipilimumab could not be excluded as per investigator.</s></p><p><s>Our phase II trial was limited by several factors; (1) the single-arm, non-randomized phase II design, however, at the time of study enrollment, no clear standard therapy for pretreated metastatic melanoma, especially for metastatic mucosal melanoma existed, (2) the small sample sizes of patients with mucosal and occult melanoma, (3) the lack of central review of imaging studies, and (4) the missing classification of tumor assessments according to immune-related response criteria <ref type="bibr" target="#b37">[37]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Conclusions</head><p><s>In conclusion, ipilimumab is a treatment option for patients with advanced cutaneous melanoma seen in daily routine.</s><s>Given the small number of patients with metastatic mucosal and occult melanoma, it is not possible to determine whether ipilimumab has activity in these melanoma subgroups.</s><s>The ALC at week 4 appears to be an early biomarker of response and need further confirmation in randomized controlled trials.</s><s>Immune-related AEs were manageable and reversible in most of the cases.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Authors' contributions</head><p><s>LZ and DS devised the study concept.</s><s>DS served as study sponsor and coordinating investigator.</s><s>All authors were responsible for data acquisition, data assembly and quality control of the data, and reviewed the study report.</s><s>LZ wrote the manuscript.</s><s>All authors read and approved the final manuscript.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Fig. 1</head><label>1</label><figDesc><div><p><s>Fig. 1 Kaplan-Meier curves for 1-year overall survival (OS) rates of different melanoma subtypes.</s><s>Pretreated patients with a metastatic cutaneous melanoma (1-year OS rate: 38 %), b mucosal melanoma (1-year OS rate: 14 %), and c occult melanoma (1-year OS rate: 27 %).</s><s>All patients received ipilimumab 3 mg/kg</s></p></div></figDesc><graphic coords="6,62.75,96.38,470.52,208.68" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Fig. 2</head><label>2</label><figDesc><div><p><s>Fig.2Kaplan-Meier curves for overall survival (OS) of subgroups (pretreated patients with metastatic cutaneous melanoma).</s><s>Subgroups were stratified as follows: by a the absence of brain metastases before the first dose of ipilimumab; Absence of brain metastases: median OS 12.3 months (95 % CI 6.0-19.4);</s><s>brain metastases present: median OS 4.2 months (95 % CI 2.0-6.1);</s><s>b the number of ipilimumab doses (4 versus &lt;4); 4 doses: median OS 13.5 months (95 % CI 7.9-20.4);</s><s>&lt;4 doses: median OS 2.1 months (95 % CI 1.6-4.1);</s><s>and c the absolute lymphocyte count (ALC) (≥1000/ µl versus &lt;1000/µl) before the second dose (i.e.</s><s>week 4) of ipilimumab; ALC ≥1000/µl: median OS 9.9 months (95 % CI 6.1-18.5);</s><s>ALC &lt;1000/µl: median OS 3.6 months (95 % CI 1.8-5.6)</s></p></div></figDesc><graphic coords="7,62.75,96.38,470.52,204.96" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1 Baseline patient characteristics (n = 103 patients totally)</head><label>1</label><figDesc></figDesc><table><row><cell>Patient characteristics</cell><cell cols="2">Cutaneous melanoma</cell><cell cols="2">Mucosal melanoma</cell><cell cols="2">Melanoma of unknown</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>primary</cell><cell></cell></row><row><cell></cell><cell>N</cell><cell>%</cell><cell>N</cell><cell>%</cell><cell>N</cell><cell>%</cell></row><row><cell>No. patients, %</cell><cell>83</cell><cell>100</cell><cell>7</cell><cell>100</cell><cell>13</cell><cell>100</cell></row><row><cell>Age, years</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Median (range)</cell><cell>63</cell><cell>(29-85)</cell><cell>63</cell><cell>(33-37)</cell><cell>62</cell><cell>(40-77)</cell></row><row><cell>Sex</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Male</cell><cell>53</cell><cell>64</cell><cell>2</cell><cell>29</cell><cell>11</cell><cell>29</cell></row><row><cell>Female</cell><cell>30</cell><cell>36</cell><cell>5</cell><cell>71</cell><cell>2</cell><cell>71</cell></row><row><cell>ECOG baseline</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>0</cell><cell>51</cell><cell>61</cell><cell>2</cell><cell>29</cell><cell>12</cell><cell>92</cell></row><row><cell>1</cell><cell>23</cell><cell>28</cell><cell>5</cell><cell>71</cell><cell>1</cell><cell>8</cell></row><row><cell>2</cell><cell>9</cell><cell>11</cell><cell>-</cell><cell></cell><cell>-</cell><cell></cell></row><row><cell>BRAF mutation</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Not mutated</cell><cell>29</cell><cell>35</cell><cell>3</cell><cell>43</cell><cell>5</cell><cell>39</cell></row><row><cell>Mutated</cell><cell>17</cell><cell>21</cell><cell>-</cell><cell></cell><cell>6</cell><cell>46</cell></row><row><cell>Not known</cell><cell>37</cell><cell>45</cell><cell>4</cell><cell>57</cell><cell>2</cell><cell>15</cell></row><row><cell>Disease stage (all: Stage IV)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>M1a</cell><cell>6</cell><cell>7</cell><cell>-</cell><cell></cell><cell>3</cell><cell>23</cell></row><row><cell>M1b</cell><cell>15</cell><cell>18</cell><cell>2</cell><cell>29</cell><cell>1</cell><cell>8</cell></row><row><cell>M1c</cell><cell>62</cell><cell>75</cell><cell>5</cell><cell>71</cell><cell>9</cell><cell>69</cell></row><row><cell>LDH</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>&lt;2 ULN</cell><cell>67</cell><cell>81</cell><cell>5</cell><cell>71</cell><cell>11</cell><cell>85</cell></row><row><cell>≥2 ULN Brain metastases</cell><cell>16</cell><cell>19</cell><cell>2</cell><cell>29</cell><cell>2</cell><cell>15</cell></row><row><cell>No</cell><cell>57</cell><cell>69</cell><cell>5</cell><cell>71</cell><cell>10</cell><cell>77</cell></row><row><cell>Yes</cell><cell>26</cell><cell>31</cell><cell>2</cell><cell>29</cell><cell>3</cell><cell>23</cell></row><row><cell cols="2">Prior systemic therapy in stage IV (except radiotherapy)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>No</cell><cell>-</cell><cell></cell><cell>-</cell><cell></cell><cell>-</cell><cell></cell></row><row><cell>Yes</cell><cell>83</cell><cell>100</cell><cell>7</cell><cell>100</cell><cell>13</cell><cell>100</cell></row><row><cell>Number of prior systemic therapies</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>1</cell><cell>42</cell><cell>51</cell><cell>6</cell><cell>86</cell><cell>8</cell><cell>62</cell></row><row><cell>2</cell><cell>27</cell><cell>33</cell><cell>-</cell><cell></cell><cell>3</cell><cell>23</cell></row><row><cell>≥3 Not applicable</cell><cell>13 1</cell><cell>16 1</cell><cell>1 -</cell><cell>14</cell><cell>2 -</cell><cell>15</cell></row><row><cell>Immunotherapy</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>No</cell><cell>67</cell><cell>81</cell><cell>7</cell><cell>100</cell><cell>11</cell><cell>85</cell></row><row><cell>Yes</cell><cell>16</cell><cell>19</cell><cell>-</cell><cell></cell><cell>2</cell><cell>15</cell></row><row><cell>If yes, type of previous immunotherapy</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Interferon alpha</cell><cell>11</cell><cell>13</cell><cell>-</cell><cell></cell><cell>2</cell><cell>15</cell></row><row><cell>Vaccination</cell><cell>5</cell><cell>6</cell><cell>-</cell><cell></cell><cell>-</cell><cell></cell></row><row><cell>Kinase inhibitors</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>No</cell><cell>71</cell><cell>86</cell><cell>7</cell><cell>100</cell><cell>9</cell><cell>69</cell></row><row><cell>Yes</cell><cell>12</cell><cell>14</cell><cell>-</cell><cell></cell><cell>4</cell><cell>31</cell></row><row><cell>If yes, type of previous kinase inhibitor</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>BRAF inhibitor</cell><cell>7</cell><cell>8</cell><cell>-</cell><cell></cell><cell>2</cell><cell>15.5</cell></row><row><cell>MEK inhibitor</cell><cell>4</cell><cell>5</cell><cell></cell><cell></cell><cell>2</cell><cell>15.5</cell></row><row><cell>Chemotherapy</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>0</cell><cell>9</cell><cell>11</cell><cell>-</cell><cell></cell><cell>2</cell><cell>15</cell></row><row><cell>1</cell><cell>47</cell><cell>57</cell><cell>6</cell><cell>86</cell><cell>8</cell><cell>62</cell></row></table><note><p><s>administration.Six-month rate for PFS were 16 % (95 % CI 9-25) for cutaneous melanoma, 14 % (95 % CI 1-47) for mucosal melanoma, and 17 % (95 % CI 3-41) for occult melanoma.Median OS from the first dose of ipilimumab for cutaneous, mucosal and occult melanoma were 6.8 (95 % CI 5.3-9.9;Fig.1a),9.6 (95 % CI 1.6-11.1;Fig.1b)</s><s>and 9.9 (lower 95 % CI 2.3, upper 95 % CI nonexistent; Fig.</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table 4 )</head><label>4</label><figDesc><div><p><s>. Treatment-related AEs were reported in 71 patients (69 %); 20 patients (19 %) had treatment-related grade 3 or 4 AEs.</s><s>The majority of ECOG Eastern Cooperative Oncology Group, LDH lactate dehydrogenase</s></p></div></figDesc><table /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head>Table 1 continued</head><label>1</label><figDesc></figDesc><table><row><cell>Patient characteristics</cell><cell cols="2">Cutaneous melanoma</cell><cell cols="2">Mucosal melanoma</cell><cell cols="2">Melanoma of unknown</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>primary</cell><cell></cell></row><row><cell></cell><cell>N</cell><cell>%</cell><cell>N</cell><cell>%</cell><cell>N</cell><cell>%</cell></row><row><cell>2</cell><cell>20</cell><cell>24</cell><cell>-</cell><cell></cell><cell>2</cell><cell>15</cell></row><row><cell>≥3</cell><cell>7</cell><cell>8</cell><cell>1</cell><cell>14</cell><cell>1</cell><cell>8</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_3"><head>Table 2 Outcomes of patients with ipilimumab re-induction therapy</head><label>2</label><figDesc></figDesc><table><row><cell>Age,</cell><cell>Best response at week</cell><cell>Duration between 1st</cell><cell>Response at 1st restag-</cell><cell>Best overall response</cell><cell>Time from 1st dose</cell><cell>Alive</cell></row><row><cell>years</cell><cell>12 (RECIST)</cell><cell>restaging (week 12)</cell><cell>ing after re-induction</cell><cell>after re-induction</cell><cell>to death/follow-up</cell><cell></cell></row><row><cell></cell><cell></cell><cell>and re-induction therapy</cell><cell>(RECIST)</cell><cell>(RECIST)</cell><cell>(months)</cell><cell></cell></row><row><cell></cell><cell></cell><cell>(days)</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>74</cell><cell>PR</cell><cell>91</cell><cell>SD</cell><cell>SD</cell><cell>17.1</cell><cell>Yes</cell></row><row><cell>56</cell><cell>PR</cell><cell>232</cell><cell>PR</cell><cell>CR</cell><cell>25.5</cell><cell>Yes</cell></row><row><cell>73</cell><cell>PR</cell><cell>217</cell><cell>PD</cell><cell>SD</cell><cell>24.8</cell><cell>Yes</cell></row></table><note><p><s>RECIST response evaluation criteria in solid tumors, PR partial response, SD stable disease, PD progressive disease</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_4"><head>Table 3 Overall</head><label>3</label><figDesc></figDesc><table><row><cell></cell><cell cols="2">Cutaneous melanoma</cell><cell cols="2">Mucosal melanoma</cell><cell>Melanoma</cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>of unknown</cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>primary</cell><cell></cell></row><row><cell></cell><cell>N</cell><cell>%</cell><cell>N</cell><cell>%</cell><cell>N</cell><cell>%</cell></row><row><cell>No. patients (%)</cell><cell>55</cell><cell>100</cell><cell>6</cell><cell>100</cell><cell>9</cell><cell>100</cell></row><row><cell>Response pattern (acc. to RECIST)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Complete response</cell><cell>-</cell><cell></cell><cell>-</cell><cell></cell><cell>-</cell><cell></cell></row><row><cell>Partial response</cell><cell>9</cell><cell>16</cell><cell>1</cell><cell>17</cell><cell>1</cell><cell>11</cell></row><row><cell>Stable disease</cell><cell>7</cell><cell>13</cell><cell>2</cell><cell>33</cell><cell>1</cell><cell>11</cell></row><row><cell>Progressive disease</cell><cell>39</cell><cell>71</cell><cell>3</cell><cell>50</cell><cell>7</cell><cell>78</cell></row><row><cell>Best ORR (according to RECIST)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>ORR (=CR + PR) ORR at week 12</cell><cell>9 7</cell><cell>16 13</cell><cell>1 1</cell><cell>17 17</cell><cell>1 -</cell><cell>11</cell></row><row><cell>ORR at week 24</cell><cell>6</cell><cell>11</cell><cell>1</cell><cell>17</cell><cell>-</cell><cell></cell></row><row><cell>Best DCR (according to RECIST)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>DCR (=CR + PR + SD) DCR at week 12</cell><cell>16 15</cell><cell>29 27</cell><cell>3 3</cell><cell>50 50</cell><cell>2 2</cell><cell>22 22</cell></row><row><cell>DCR at week 24</cell><cell>10</cell><cell>18</cell><cell>1</cell><cell>17</cell><cell>1</cell><cell>11</cell></row></table><note><p><s>response rates (ORR) and disease control rates (DCR) (n = 70 patients totally) CR complete response, PR partial response, RECIST response evaluation criteria in solid tumors, SD stable disease Patients with measurable disease (and at least one tumor assessment)</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_5"><head>Table 4 Reported adverse events in overall study population (n = 103 patients totally)</head><label>4</label><figDesc></figDesc><table><row><cell>Adverse events (AE) a</cell><cell cols="2">Cutaneous melanoma</cell><cell cols="2">Mucosal melanoma</cell><cell>MUP</cell><cell></cell><cell>Total</cell><cell></cell></row><row><cell>No. patients (%)</cell><cell>83 (100)</cell><cell></cell><cell>7 (100)</cell><cell></cell><cell>13 (100)</cell><cell></cell><cell>103 (100)</cell><cell></cell></row><row><cell></cell><cell>All grades</cell><cell>Grade 3/4</cell><cell>All grades</cell><cell>Grade 3/4</cell><cell>All grades</cell><cell>Grade 3/4</cell><cell>All grades</cell><cell>Grade 3/4</cell></row><row><cell>Patients with at least one AE</cell><cell>79 (95)</cell><cell>36 (43)</cell><cell>6 (86)</cell><cell>4 (57)</cell><cell>13 (100)</cell><cell>7 (54)</cell><cell>98 (95)</cell><cell>47 (46)</cell></row><row><cell>Patients with treatment-related AE</cell><cell>57 (69)</cell><cell>14 (17)</cell><cell>3 (43)</cell><cell>2 (29)</cell><cell>11 (85)</cell><cell>4 (31)</cell><cell>71 (69)</cell><cell>20 (19)</cell></row><row><cell>Patients with any irAE</cell><cell>40 (48)</cell><cell>12</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table><note><p><s>ir immune related, GI gastrointestinal, ALT alanine aminotransferases, AST aspartate aminotransferases, MUP melanoma of unknown primary a Patients may have had more than one adverse event b Other gastrointestinal disorders were abdominal pain (n = 6 grade 1/2; n = 3 grade 3/4), constipation (n = 1 grade 1/2) and elevated lipase (n = 1 grade 3/4)</s></p></note></figure>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Acknowledgements</head><p><s>The authors are grateful to patients, their families and staff at the study sites and thank the Alcedis team for statistical support.</s><s>Editorial and writing assistance was provided by Dr. Markus Hartmann, funded by Bristol-Myers Squibb.</s></p></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Funding</head><p><s>DS received funding by Bristol Myers-Squibb for the DeCOG-MM-PAL11 trial.</s><s>Bristol-Myers Squibb study number: CA184-137; http://www.b-ms.de.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Role of the funding source</head><p><s>The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</s><s>The authors had the final responsibility in submitting the manuscript for publication.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Competing interests</head><p><s>Lisa Zimmer has served as consultant and received speaker's honoraria and meeting support from Roche, Bristol-Myers Squibb, MSD Sharp &amp; Dohme, Novartis, Merck and GlaxoSmithKline.</s><s>Thomas K. Eigentler has served in a consultant/advisory role for Bristol-Myers Squibb and has received honoraria from Genentech/Roche, Bristol-Myers Squibb and Amgen.</s><s>Felix Kieker has served in a consultancy/advisory role for MSD Sharp &amp; Dohme, Brisol-Myers Squibb, Roche, GlaxoSmithKline, Novartis and Amgen.</s><s>Jan Simon has served in a consultancy/advisory role for Novartis, Roche Pharma and has received support to attend meetings from Merck Sharp &amp; Dohme.</s><s>Jochen Utikal has served in consultancy/advisory role for Roche and Glaxo SmithKline (GSK).</s><s>Peter Mohr has served in a consultant/advisory role for MSD Sharp &amp; Dohme (MSD), Leo Pharma, Novartis, GSK, Bristol Myers Squibb, PPD, Hoffmann La Roche, Quintiles.</s><s>Carola Berking has served in a consultancy/advisory role for Amgen, AstraZeneca, BMS, GSK, MSD, Novartis, and Roche, she has received speaker´s</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Additional files</head><p><s>Additional file 1: Figure <ref type="figure">S1</ref>.</s><s>Consort Diagram.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Additional file 2. Protocol DeCOG -MM-PAL11-Trial.</head><p><s>Additional file 3: Table <ref type="table">S3</ref>.</s><s>Patients with different response pattern in intracranial and extracranial metastases.</s></p><p><s>Additional file 4: Table <ref type="table">S4</ref>.</s><s>Summarized data a reporting the efficacy of ipilimumab 3 mg/kg in clinical-practice-settings incl.</s><s>EAP.</s><s>honoraria by BMS, GSK, MSD, Novartis, and Roche and she has received support to attend scientific meetings by BMS, MSD, and Roche.</s><s>Eckhart Kämpgen received travel expenses and honoraries from Bristol Myers Squibb, fees from GSK and Roche, and served in an advisory role for Beckmann-Coulter.</s><s>Rudolf Stadler has served as in consultancy/advisory role for Roche and Galderma.</s><s>Axel Hauschild has served in a consultancy role for Amgen, BMS, Celgene, Eisai, GSK, MedImmune, MelaSciences, Merck Serono, MSD Sharp &amp; Dohme, Novartis, Oncosec, Roche Pharma and received honoraries and trial grants (except from MedImmune) from these corporations.</s><s>Patrick Terheyden has served in an advisory role for Roche, BMS, Amgen, and GKS with honoraria received from BMS and Roche.</s><s>Carmen Loquai has served in an advisory role for BMS, Roche, MSD, Novartis, Amgen, receiving honoraria from BMS, Roche, MSD and reimbursement for travel expenses from BMS, Roche, MSD and Novartis.</s><s>Claus Garbe reports grants and personal fees from BMS during the conduct of the study; personal fees from Amgen, MSD and Novatis, and grants and personal fees from GSK and Roche outside the submitted work.</s><s>Dirk Schadendorf has served on advisory boards and on speaker´s bureaus of the following companies: Amgen, Boehringer Ingelheim, BMS, Delcath, GSK, Merck-Serono, MSD, Novartis, and Roche; he also served as consultant for BMS, GSK, MSD and Novartis and his institute received research funding from MSD and BMS.</s><s>None of the remaining authors have any competing interests todisclose.</s></p><p><s>Received: 3 July 2015 Accepted: 26 October 2015</s></p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Breakthrough of the year 2013</title>
		<author>
			<persName><forename type="first">J</forename><surname>Couzin-Frankel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer immunotherapy. Science</title>
		<imprint>
			<biblScope unit="volume">342</biblScope>
			<biblScope unit="page" from="1432" to="1433" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Weber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">P</forename><surname>Angelo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Minor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">S</forename><surname>Hodi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Gutzmer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Neyns</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet Oncol</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page" from="375" to="384" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Antiprogrammed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial</title>
		<author>
			<persName><forename type="first">C</forename><surname>Robert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Ribas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Wolchok</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">S</forename><surname>Hodi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Hamid</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Kefford</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">384</biblScope>
			<biblScope unit="page" from="1109" to="1117" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">A randomized controlled comparison of pembrolizumab and chemotherapy in patients with ipilimumab-refractory melanoma</title>
		<author>
			<persName><forename type="first">R</forename><surname>Dummer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Daud</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Puzanov</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Hamid</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Schadendorf</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Robert</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Transl Med</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page">2062</biblScope>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial</title>
		<author>
			<persName><forename type="first">A</forename><surname>Ribas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Puzanov</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Dummer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Schadendorf</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Hamid</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Robert</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet Oncol</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page" from="908" to="918" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Improved survival with ipilimumab in patients with metastatic melanoma</title>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">S</forename><surname>Hodi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>O'day</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">F</forename><surname>Mcdermott</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">W</forename><surname>Weber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Sosman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">B</forename><surname>Haanen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">363</biblScope>
			<biblScope unit="page" from="711" to="723" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Ipilimumab plus dacarbazine for previously untreated metastatic melanoma</title>
		<author>
			<persName><forename type="first">C</forename><surname>Robert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Thomas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Bondarenko</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>O'day</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Dj</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Garbe</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">364</biblScope>
			<biblScope unit="page" from="2517" to="2526" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Immune checkpoint blockade in cancer therapy</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Postow</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">K</forename><surname>Callahan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Wolchok</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">33</biblScope>
			<biblScope unit="page" from="1974" to="1982" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">A</forename><surname>Ott</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">S</forename><surname>Hodi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Robert</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Cancer Res</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="page" from="5300" to="5309" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Distinct sets of genetic alterations in melanoma</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Curtin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Fridlyand</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Kageshita</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">N</forename><surname>Patel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">J</forename><surname>Busam</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Kutzner</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">353</biblScope>
			<biblScope unit="page" from="2135" to="2147" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Phase II DeCOG-study of ipilimumab in pretreated and treatment-naive patients with metastatic uveal melanoma</title>
		<author>
			<persName><forename type="first">L</forename><surname>Zimmer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Vaubel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Mohr</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Hauschild</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Utikal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Simon</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">PLoS One</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page">e0118564</biblScope>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Final version of 2009 AJCC melanoma staging and classification</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Balch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Gershenwald</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Soong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">F</forename><surname>Thompson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">B</forename><surname>Atkins</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">R</forename><surname>Byrd</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="page" from="6199" to="6206" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">A</forename><surname>Eisenhauer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Therasse</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Bogaerts</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">H</forename><surname>Schwartz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Sargent</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Ford</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Cancer</title>
		<imprint>
			<biblScope unit="volume">45</biblScope>
			<biblScope unit="page" from="228" to="247" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Effectiveness and tolerability of ipilimumab: experiences from 198 patients included in a named-patient program in various daily-practice settings and multiple institutions</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">K</forename><surname>Eigentler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Schlaak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Hassel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Loquai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Stoffels</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Gutzmer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Immunother</title>
		<imprint>
			<biblScope unit="volume">37</biblScope>
			<biblScope unit="page" from="374" to="381" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">A</forename><surname>Ascierto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Simeone</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">C</forename><surname>Sileni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Pigozzo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Maio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Altomonte</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Transl Med</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page">116</biblScope>
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Ipilimumab for advanced melanoma: experience from the Spanish Expanded Access Program</title>
		<author>
			<persName><forename type="first">A</forename><surname>Berrocal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Arance</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Lopezmartin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Soriano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Munoz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Alonso</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Melanoma Res</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="page" from="577" to="583" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Ipilimumab in pretreated patients with unresectable or metastatic cutaneous, uveal and mucosal melanoma</title>
		<author>
			<persName><forename type="first">M</forename><surname>Alexander</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Mellor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Mcarthur</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Kee</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Med J Aust</title>
		<imprint>
			<biblScope unit="volume">201</biblScope>
			<biblScope unit="page" from="49" to="53" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma</title>
		<author>
			<persName><forename type="first">S</forename><surname>Kelderman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Heemskerk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Van Tinteren</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">R</forename><surname>Van Den Brom</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">A</forename><surname>Hospers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Van Den Eertwegh</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Immunol Immunother</title>
		<imprint>
			<biblScope unit="volume">63</biblScope>
			<biblScope unit="page" from="449" to="458" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Wolchok</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Neyns</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Linette</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Negrier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Lutzky</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Thomas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet Oncol</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page" from="155" to="164" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma</title>
		<author>
			<persName><forename type="first">D</forename><surname>Schadendorf</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">S</forename><surname>Hodi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Robert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Weber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Margolin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Hamid</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">33</biblScope>
			<biblScope unit="page" from="1889" to="1894" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Efficacy and safety of ipilimumab 3 mg/kg in patients with pretreated, metastatic, mucosal melanoma</title>
		<author>
			<persName><forename type="first">Del</forename><surname>Vecchio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename></persName>
		</author>
		<author>
			<persName><forename type="first">Di</forename><surname>Guardo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Ascierto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">A</forename><surname>Grimaldi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Sileni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">C</forename><surname>Pigozzo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Cancer</title>
		<imprint>
			<biblScope unit="volume">50</biblScope>
			<biblScope unit="page" from="121" to="127" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Ipilimumab for patients with advanced mucosal melanoma</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Postow</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Luke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Bluth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Ramaiya</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">S</forename><surname>Panageas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">P</forename><surname>Lawrence</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Oncologist</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="page" from="726" to="732" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Improved survival for stage IV melanoma from an unknown primary site</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">C</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">B</forename><surname>Faries</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>Wanek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">L</forename><surname>Morton</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="page" from="3489" to="3495" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Malignant melanoma of unknown primary site. To make the long story short. A systematic review of the literature</title>
		<author>
			<persName><forename type="first">K</forename><surname>Kamposioras</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Pentheroudakis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Pectasides</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Pavlidis</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Crit Rev Oncol Hematol</title>
		<imprint>
			<biblScope unit="volume">78</biblScope>
			<biblScope unit="page" from="112" to="126" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Melanoma of unknown primary origin: a population-based study in the Netherlands</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">C</forename><surname>De Waal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">K</forename><surname>Aben</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">M</forename><surname>Van Rossum</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>Kiemeney</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Cancer</title>
		<imprint>
			<biblScope unit="volume">49</biblScope>
			<biblScope unit="page" from="676" to="683" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival</title>
		<author>
			<persName><forename type="first">J</forename><surname>Delyon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Mateus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Lefeuvre</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Lanoy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Zitvogel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Chaput</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Oncol</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="page" from="1697" to="1703" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">Y</forename><surname>Ku</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Yuan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">B</forename><surname>Page</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">E</forename><surname>Schroeder</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">S</forename><surname>Panageas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">D</forename><surname>Carvajal</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer</title>
		<imprint>
			<biblScope unit="volume">116</biblScope>
			<biblScope unit="page" from="1767" to="1775" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Single-center experience with ipilimumab in an expanded access program for patients with pretreated advanced melanoma</title>
		<author>
			<persName><forename type="first">S</forename><surname>Wilgenhof</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Du</forename><surname>Four</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Vandenbroucke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Everaert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Salmon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Lienard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Immunother</title>
		<imprint>
			<biblScope unit="volume">36</biblScope>
			<biblScope unit="page" from="215" to="222" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma</title>
		<author>
			<persName><forename type="first">E</forename><surname>Simeone</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Gentilcore</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Giannarelli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Grimaldi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Caraco</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Curvietto</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Immunol Immunother</title>
		<imprint>
			<biblScope unit="volume">63</biblScope>
			<biblScope unit="page" from="675" to="683" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Safety, activity, and immune correlates of anti-PD-1 antibody in cancer</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">L</forename><surname>Topalian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">S</forename><surname>Hodi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Brahmer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">N</forename><surname>Gettinger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">C</forename><surname>Smith</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">F</forename><surname>Mcdermott</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">366</biblScope>
			<biblScope unit="page" from="2443" to="2454" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<monogr>
		<title level="m" type="main">Association of tumor PD-L1 expression and immune biomarkers with clinical activity in patients (pts) with advanced solid tumors treated with nivolumab</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">F</forename><surname>Grosso</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">E</forename><surname>Horak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Inzunza</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Cardona</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Simon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">A</forename><surname>Kumar</surname></persName>
		</author>
		<imprint/>
	</monogr>
	<note>anti-PD-1; BMS-936558</note>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">ONO-4538)</title>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="page">3016</biblScope>
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note>suppl</note>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">Nivolumab in Previously Untreated Melanoma without BRAF Mutation</title>
		<author>
			<persName><forename type="first">C</forename><surname>Robert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">V</forename><surname>Long</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Brady</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Dutriaux</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Maio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Mortier</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">372</biblScope>
			<biblScope unit="page" from="320" to="330" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">Combined nivolumab and ipilimumab or monotherapy in untreated melanoma</title>
		<author>
			<persName><forename type="first">J</forename><surname>Larkin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Chiarion-Sileni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Gonzalez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Grob</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">L</forename><surname>Cowey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">D</forename><surname>Lao</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">373</biblScope>
			<biblScope unit="page" from="23" to="34" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">Pembrolizumab versus ipilimumab in advanced melanoma</title>
		<author>
			<persName><forename type="first">C</forename><surname>Robert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Schachter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">V</forename><surname>Long</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Arance</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Grob</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Mortier</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">372</biblScope>
			<biblScope unit="page" from="2521" to="2532" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">Nivolumab and ipilimumab versus ipilimumab in untreated melanoma</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Postow</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Chesney</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">C</forename><surname>Pavlick</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Robert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Grossmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Mcdermott</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">372</biblScope>
			<biblScope unit="page" from="2006" to="2017" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications</title>
		<author>
			<persName><forename type="first">Di</forename><surname>Giacomo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Biagioli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Maio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Semin Oncol</title>
		<imprint>
			<biblScope unit="volume">37</biblScope>
			<biblScope unit="page" from="499" to="507" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Wolchok</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Hoos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>O'day</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Weber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Hamid</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Lebbe</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Cancer Res</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page" from="7412" to="7420" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
